On 6 May 2015, the European Commission withdrew the marketing authorization for Provenge in the European Union (EU) (European Medicines Agency, MAY 11, 2015, View Source [SID:1234511747]). The withdrawal was at the request of Dendreon, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reason.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!